

Lumito's Scientific Advisory Board Meeting Held and Additional Key Opinion Leader Joins

Following the establishment of its Scientific Advisory Board (SAB) announced on 5 June 2025, the SAB held a meeting this week, where the uniqueness of Lumito's solution, Scizys, was confirmed and reaffirmed as a promising technology with the potential to lead the way in quantitative tissue analysis and pathology. Lumito are pleased to announce that an additional key opinion leader, Pascal Bamford, has joined Lumito's Scientific Advisory Board and participated in the meeting.

"I was especially encouraged by the shared view among the board members that we truly have a unique solution that addresses clear needs in pharmaceutical development. Accurately quantifying low levels of biological markers is essential for understanding drug mechanisms and identifying patients eligible for treatment", comments Sanna Wallenborg, CEO of Lumito.

The discussions focused on two strategic areas: accelerating go-to-market activities and exploring applications within the pharmaceutical development sector. The board expressed strong consensus that Lumito has demonstrated solid proof of product and is currently in the proof of business phase, following the CE marking of Scizys.

"Adding Pascal Bamford to our, already highly regarded SAB, is truly an honour. His competence and experience in our field, including market introduction of new technologies as well as nanoparticles and image analysis proved its value already in this first SAB. I am looking forward to future interactions with Pascal and the rest of our advisory board", finishes Sanna Wallenborg.

Pascal Bamford, PhD – technical expert in image analysis, digital pathology and oncology diagnostics with over 25 years of experience. Has held leadership roles at Roche Tissue Diagnostics, Epic Sciences and Akoya Biosciences. Currently Chief Clinical Officer at Akoya Biosciences.

Chair of the SAB, Paul Waring, shares highlights from the meeting in a video summary, [link here](#).

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

Attachments

[Lumito's Scientific Advisory Board Meeting Held and Additional Key Opinion Leader Joins](#)